In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.
Medscape Medical News
Original Article: Go Low With Tamoxifen for DCIS